In terms of immunotherapies, in July 2019, the FDA approved the PD1 inhibitor pembrolizumab for second-line treatment of PDL1-positive, advanced or metastatic ESCC. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.